<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01134731</url>
  </required_header>
  <id_info>
    <org_study_id>F100329001</org_study_id>
    <nct_id>NCT01134731</nct_id>
  </id_info>
  <brief_title>Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation</brief_title>
  <acronym>AFSP</acronym>
  <official_title>Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Foundation for Suicide Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ortho-McNeil Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to use a combined clinical and translational approach to identify an efficient
      pharmacotherapy for the acute management of suicidality and the epigenetic regulation
      associated with the treatment.The primary objective is a clinical trial to compare the
      efficacy of paliperidone versus lithium and placebo as adjunctive therapy to the standard of
      care antidepressants in the acute management of suicidality in depressed subjects.

      Specific Aims 1 and 2 are described in detail below. Analysis for Specific Aim 2 is still
      underway.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aim 1: The atypical antipsychotic, paliperidone, when initiated simultaneously with
      an antidepressant, is superior to lithium plus antidepressant in the early intervention of
      suicidality in patients with Major Depressive Disorder (MDD). The goal of this aim is to
      examine the clinical efficacy of paliperidone in reducing suicidality, with a focus on early
      intervention. The hypothesis is based on our recently completed pilot study in which we found
      that the atypical antipsychotic, risperidone, had a rapid onset of action to reduce
      suicidality in patients with MDD. In view of a shortage in acute pharmacological management
      of suicidality, this study will provide an important new treatment option for the life
      threatening psychiatric condition.

      Specific Aim 2: Both paliperidone and lithium regulate epigenetics by stabilizing DNA
      methylation, which is correlated with inhibition of glycogen synthase kinase-3 (GSK3)
      activity and improved clinical symptoms. This exploratory aim is developed based on the
      recent findings that DNA methylation is involved in regulation of mood, behavior, and
      cognition, and the enzyme of this epigenetic mechanism - DNA methyltransferase-1 (DNMT1) is
      regulated by the therapeutic target Glycogen synthase kinase 3 (GSK3). We will measure the
      expression of DNMTs and DNA methylation of global DNA, Brain-derived neurotrophic factor
      (BDNF), and Tropomyosin receptor kinase B (TrkB) in peripheral blood before and after study
      drug treatment, and analyze their correlation with GSK3 activity and clinical symptoms in
      response to treatment. Outcomes from this study will provide important new information in
      future development of more effective treatment options for suicidality targeting epigenetic
      regulation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Score of Beck Scale for Suicidal Ideation of Three Treatment Groups (Paliperidone, Lithium and Placebo) After 3 Months of Treatment</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>The Beck Scale for Suicidal Ideation will be used to measure the efficacy of the study drugs. The primary outcome measure is the Beck Suicide Scale Self Report. The primary outcome measure is the Beck Suicide Scale Self Report. It has 21 questions (subscales) with values ranging from 0-2. Therefore the total score ranges from 0-42, with lower scores indicating better outcomes. The subscales were summed to achieve a total score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Score of Montgomery-Asberg Depression Scale of Three Treatment Groups (Paliperidone, Lithium and Placebo) After 3 Months of Treatment</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>The Montgomery-Asberg Depression Rating Scale will be used to measure depressive symptoms to determine the efficacy of the study drugs. It has 10 items (subscales) ranging from 0-6. Therefore the total score ranges from 0-60, with lower scores indicating better outcomes. The subscales were summed for a total score.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Suicidal Ideation</condition>
  <arm_group>
    <arm_group_label>paliperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose escalation , levels 1-5 daily dosing ranged from 1-5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lithium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dose escalation, level 1-5 daily dosing 300-1500mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1-5 placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paliperidone</intervention_name>
    <description>1-5 mg daily (QD)</description>
    <arm_group_label>paliperidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lithium</intervention_name>
    <description>300-1500mg QD</description>
    <arm_group_label>lithium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1-5 placebo capsules</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects who are able to provide informed consent

          2. 19-65 years of age

          3. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) diagnosis
             of MDD by MINI International Neuropsychiatric Interview (MINI) and confirmed by
             psychiatric interview

          4. Currently experiencing a depressive episode with suicidality (defined as having
             current suicidal thoughts occurring at least 3 out of 7 days in a week).

          5. Montgomery-Asberg Depression Rating Scale (MADRS) must include a total score &gt; 25 and
             a suicidal sub-score &gt; 4.

        Exclusion Criteria:

          1. Depressed patients without suicidality, patients with severe psychotic features or
             with primary diagnoses of bipolar disorder (BD), schizophrenia, schizoaffective
             disorder, or generalized anxiety disorder (GAD), and subjects who have been taking
             lithium or an antipsychotic in the past 2 weeks

          2. Those with uncontrolled medical illnesses. Participants must be on any new medications
             for at least 30 days to be considered medically stable.

          3. For patients with panic disorder, post-traumatic stress disorder (PTSD), borderline
             personality disorder (BPD), etc. be sure that MDD is the primary diagnosis. When in
             doubt, decisions will be made on a case-by-case basis.

          4. Pregnant women.

          5. Allergic to paliperidone, to any other ingredient in paliperidone ER or paliperidone
             palmitate, or to risperidone.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard C Shelton, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2010</study_first_submitted>
  <study_first_submitted_qc>June 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2010</study_first_posted>
  <results_first_submitted>May 26, 2015</results_first_submitted>
  <results_first_submitted_qc>December 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 29, 2016</results_first_posted>
  <last_update_submitted>February 3, 2016</last_update_submitted>
  <last_update_submitted_qc>February 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Dr. Richard Shelton</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>suicidality</keyword>
  <keyword>Major Depressive Disorder, current episode, with suicidality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Suicidal Ideation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
    <mesh_term>Paliperidone Palmitate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were male and female, aged 19- 65 years old, recruited as outpatients from the general public.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Paliperidone</title>
          <description>dose escalation, levels 1-5 daily dosing range from 1-5 mg</description>
        </group>
        <group group_id="P2">
          <title>Lithium</title>
          <description>mood stabilizer
dose escalation levels 1-5 daily dosing lithium: 300-1500mg daily (QD)</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>1-5 capsules</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Paliperidone 1-5mg</title>
          <description>daily</description>
        </group>
        <group group_id="B2">
          <title>Lithium 600-1500mg</title>
          <description>daily</description>
        </group>
        <group group_id="B3">
          <title>Placebo 1-5 Capsules</title>
          <description>12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Score of Beck Scale for Suicidal Ideation of Three Treatment Groups (Paliperidone, Lithium and Placebo) After 3 Months of Treatment</title>
        <description>The Beck Scale for Suicidal Ideation will be used to measure the efficacy of the study drugs. The primary outcome measure is the Beck Suicide Scale Self Report. The primary outcome measure is the Beck Suicide Scale Self Report. It has 21 questions (subscales) with values ranging from 0-2. Therefore the total score ranges from 0-42, with lower scores indicating better outcomes. The subscales were summed to achieve a total score.</description>
        <time_frame>baseline to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone</title>
            <description>dose escalation , levels 1-5 daily dosing ranged from 1-5mg
paliperidone: 1-5 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Lithium</title>
            <description>dose escalation, level 1-5 daily dosing 300-1500mg
lithium: 300-1500mg QD</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo comparator, 1-5 capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Score of Beck Scale for Suicidal Ideation of Three Treatment Groups (Paliperidone, Lithium and Placebo) After 3 Months of Treatment</title>
          <description>The Beck Scale for Suicidal Ideation will be used to measure the efficacy of the study drugs. The primary outcome measure is the Beck Suicide Scale Self Report. The primary outcome measure is the Beck Suicide Scale Self Report. It has 21 questions (subscales) with values ranging from 0-2. Therefore the total score ranges from 0-42, with lower scores indicating better outcomes. The subscales were summed to achieve a total score.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1" spread="8.6"/>
                    <measurement group_id="O2" value="22.1" spread="8.6"/>
                    <measurement group_id="O3" value="21.3" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Score of Montgomery-Asberg Depression Scale of Three Treatment Groups (Paliperidone, Lithium and Placebo) After 3 Months of Treatment</title>
        <description>The Montgomery-Asberg Depression Rating Scale will be used to measure depressive symptoms to determine the efficacy of the study drugs. It has 10 items (subscales) ranging from 0-6. Therefore the total score ranges from 0-60, with lower scores indicating better outcomes. The subscales were summed for a total score.</description>
        <time_frame>baseline to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone</title>
            <description>dose escalation , levels 1-5 daily dosing ranged from 1-5mg
paliperidone: 1-5 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Lithium</title>
            <description>dose escalation, level 1-5 daily dosing 300-1500mg
lithium: 300-1500mg QD</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>1-5 placebo capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Score of Montgomery-Asberg Depression Scale of Three Treatment Groups (Paliperidone, Lithium and Placebo) After 3 Months of Treatment</title>
          <description>The Montgomery-Asberg Depression Rating Scale will be used to measure depressive symptoms to determine the efficacy of the study drugs. It has 10 items (subscales) ranging from 0-6. Therefore the total score ranges from 0-60, with lower scores indicating better outcomes. The subscales were summed for a total score.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" spread="5.6"/>
                    <measurement group_id="O2" value="39.6" spread="4.1"/>
                    <measurement group_id="O3" value="39.2" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event reporting started 3/1/2011 and stopped 10/15/2014</time_frame>
      <desc>The primary outcome variable was the Beck Scale for Suicide Ideation (BSSI, items 1-19).</desc>
      <group_list>
        <group group_id="E1">
          <title>Paliperidone</title>
        </group>
        <group group_id="E2">
          <title>Lithium</title>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The inherent risk of the condition and concerns about the safety of the study, the high risk of impulsive and aggressive behavior, and high levels of distress making placebo-controlled studies difficult. Placebo arm terminated early due to dropout.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Richard Shelton</name_or_title>
      <organization>UAB</organization>
      <phone>205-934-2484</phone>
      <email>rshelton@uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

